Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

DYRK2 Antikörper (N-Term)

DYRK2 Reaktivität: Human WB, IHC (p) Wirt: Kaninchen Polyclonal RB3008 unconjugated
Produktnummer ABIN391770
  • Target Alle DYRK2 Antikörper anzeigen
    DYRK2 (Dual-Specificity tyrosine-(Y)-phosphorylation Regulated Kinase 2 (DYRK2))
    Bindungsspezifität
    • 15
    • 11
    • 8
    • 7
    • 6
    • 5
    • 4
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    AA 105-135, N-Term
    Reaktivität
    • 47
    • 32
    • 22
    • 3
    • 3
    • 3
    • 3
    • 3
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    Human
    Wirt
    • 60
    • 7
    • 1
    Kaninchen
    Klonalität
    • 61
    • 7
    Polyklonal
    Konjugat
    • 26
    • 6
    • 6
    • 5
    • 4
    • 4
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    Dieser DYRK2 Antikörper ist unkonjugiert
    Applikation
    • 61
    • 38
    • 32
    • 13
    • 13
    • 8
    • 5
    • 3
    • 3
    • 2
    • 2
    • 1
    Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
    Aufreinigung
    This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.
    Immunogen
    This DYRK2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 105-135 amino acids from the N-terminal region of human DYRK2.
    Klon
    RB3008
    Isotyp
    Ig Fraction
  • Applikationshinweise
    WB: 1:1000. WB: 1:1000. IHC-P: 1:50~100
    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Format
    Liquid
    Buffer
    Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
    Konservierungsmittel
    Sodium azide
    Vorsichtsmaßnahmen
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Lagerung
    4 °C,-20 °C
    Informationen zur Lagerung
    Maintain refrigerated at 2-8 °C for up to 6 months. For long term storage store at -20 °C in small aliquots to prevent freeze-thaw cycles.
    Haltbarkeit
    6 months
  • Mimoto, Imawari, Hirooka, Takeyama, Yoshida: "Impairment of DYRK2 augments stem-like traits by promoting KLF4 expression in breast cancer." in: Oncogene, Vol. 36, Issue 13, pp. 1862-1872, (2017) (PubMed).

    Nomura, Suzuki, Takahashi, Terasaki, Kimata, Terasaki, Hamasaki, Kimura, Shimizu, Kondo: "Dual-specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2) as a novel marker in T1 high-grade and T2 bladder cancer patients receiving neoadjuvant chemotherapy." in: BMC urology, Vol. 15, pp. 53, (2015) (PubMed).

    Moreno, Lara-Chica, Soler-Torronteras, Caro, Medina, Álvarez, Salvatierra, Muñoz, Calzado: "The Expression of the Ubiquitin Ligase SIAH2 (Seven In Absentia Homolog 2) Is Increased in Human Lung Cancer." in: PLoS ONE, Vol. 10, Issue 11, pp. e0143376, (2015) (PubMed).

    Enomoto, Yamashita, Yoshinaga, Fukami, Miyahara, Nabeshima, Iwasaki: "Downregulation of DYRK2 can be a predictor of recurrence in early stage breast cancer." in: Tumour biology, Vol. 35, Issue 11, pp. 11021-5, (2014) (PubMed).

    Taira, Mimoto, Kurata, Yamaguchi, Kitagawa, Miki, Yoshida: "DYRK2 priming phosphorylation of c-Jun and c-Myc modulates cell cycle progression in human cancer cells." in: The Journal of clinical investigation, Vol. 122, Issue 3, pp. 859-72, (2012) (PubMed).

    Pérez, García-Limones, Zapico, Marina, Schmitz, Muñoz, Calzado: "Mutual regulation between SIAH2 and DYRK2 controls hypoxic and genotoxic signaling pathways." in: Journal of molecular cell biology, Vol. 4, Issue 5, pp. 316-30, (2012) (PubMed).

    Yamashita, Chujo, Tokuishi, Anami, Miyawaki, Yamamoto, Kawahara: "Expression of dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 2 (DYRK2) can be a favorable prognostic marker in pulmonary adenocarcinoma." in: The Journal of thoracic and cardiovascular surgery, Vol. 138, Issue 6, pp. 1303-8, (2009) (PubMed).

    Yamashita, Chujo, Moroga, Anami, Tokuishi, Miyawaki, Kawano, Takeno, Yamamoto, Kawahara: "DYRK2 expression may be a predictive marker for chemotherapy in non-small cell lung cancer." in: Anticancer research, Vol. 29, Issue 7, pp. 2753-7, (2009) (PubMed).

  • Target
    DYRK2 (Dual-Specificity tyrosine-(Y)-phosphorylation Regulated Kinase 2 (DYRK2))
    Andere Bezeichnung
    DYRK2 (DYRK2 Produkte)
    Synonyme
    DYRK2 antikoerper, fc18c09 antikoerper, si:ch211-266a5.8 antikoerper, wu:fa09g03 antikoerper, wu:fc18c09 antikoerper, 1810038L18Rik antikoerper, dual specificity tyrosine phosphorylation regulated kinase 2 antikoerper, dual specificity tyrosine-phosphorylation-regulated kinase 2 antikoerper, dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 antikoerper, DYRK2 antikoerper, CpipJ_CPIJ014802 antikoerper, dyrk2 antikoerper, Dyrk2 antikoerper
    Hintergrund
    DYRK2 belongs to a family of protein kinases whose members are presumed to be involved in cellular growth and/or development. The family is defined by structural similarity of their kinase domains and their capability to autophosphorylate on tyrosine residues. DYRK2 has demonstrated tyrosine autophosphorylation and catalyzed phosphorylation of histones H3 and H2B in vitro.
    Molekulargewicht
    66652
    Gen-ID
    8445
    NCBI Accession
    NP_003574, NP_006473
    UniProt
    Q92630
    Pathways
    Regulation of Carbohydrate Metabolic Process
Sie sind hier:
Kundenservice